Cover Image

SGLT-2 inhibitors: new effective drugs for treatment of heart failure

Introduction: SGLT-2 inhibitors having selectivity to sodium glucose cotransporter 2 were introduced on the market in 2012 as drugs for the pharmacotherapy of type 2 diabetes. Aim of the work: To summarize the current state of knowledge about the drugs: SGLT-2 inhibitors and their mechanism of actio...

Full description

Saved in:

Bibliographic Details
Main Authors:	Olgierd Król (Author), Konrad Gładysz (Author), Justyna Szydłowska (Author), Olga Żuchnik (Author), Piotr Kwiatkowski (Author), Magdalena Czelej (Author), Aleksander Kłos (Author), Krzysztof Gieroba (Author), Marcin Szydłowski (Author), Paweł Zuchniak (Author)
Format:	Book
Published:	Kazimierz Wielki University, 2022-12-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Endometriosis - Pathogenesis, diagnosis and treatment
by: Piotr Kwiatkowski, et al.
Published: (2023)

Atopic dermatitis - clinical phenotypes and related therapeutic possibilities
by: Krzysztof Gieroba, et al.
Published: (2022)

3D bioprinting as a future of regenerative medicine and hope for transplantology
by: Konrad Gładysz, et al.
Published: (2022)

Hippotherapy as an accompaniment to therapy in children with autism
by: Magdalena Czelej, et al.
Published: (2022)

Pros and cons of splenic artery embolization after mechanical splenic injury - comparison of methods.
by: Marcin Szydłowski, et al.
Published: (2022)

Hair loss after SARS-CoV2 Infection
by: Beata Kuczyńska, et al.
Published: (2022)

Idiopathic pulmonary fibrosis - problematic rare lung disease. Pathogenesis, diagnosis, treatment and prognosis
by: Aleksander Kłos, et al.
Published: (2022)

Consumption of green tea - potential health benefits
by: Olga Żuchnik, et al.
Published: (2022)

Benefits of nutritional yeast for children on vegan diet
by: Justyna Justyna, et al.
Published: (2022)

The PFAPA syndrome: review on diagnosis and management
by: Paweł Zuchniak, et al.
Published: (2022)

SGLT2-Inhibitors - significant role in Heart Failure treatment
by: Karol Wielgus, et al.
Published: (2024)

SGLT-2 inhibitors in the management of acute decompensated heart failure
by: Anastasia E. Poskakalova, et al.
Published: (2024)

The use of SGLT2 inhibitors in the treatment of cognitive disorders
by: Marta Lato, et al.
Published: (2023)

SGLT-2 inhibitors in heart failure: a literature review on mechanisms, efficacy and safety
by: Klaudia Kułak, et al.
Published: (2024)

Psoriasiform lesions as a side effect of SGLT-2 therapy
by: Jakub Krzysztof Gałązka, et al.
Published: (2023)

Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
by: Zofia Wicik, et al.
Published: (2022)

Euglycemic diabetes ketoacidosis associated with SGLT-2 inhibitors - review of case reports
by: Joanna Winciorek, et al.
Published: (2024)

Emerging concepts in heart failure treatment and management: focus on SGLT2 inhibitors in heart failure with preserved ejection fraction
by: Andrea Beatriz De Lorenzi, et al.
Published: (2023)

The New Role of SGLT2 Inhibitors in the Management of Heart Failure: Current Evidence and Future Perspective
by: Saverio Muscoli, et al.
Published: (2022)

Structural repurposing of SGLT2 inhibitor empagliflozin for strengthening anti-heart failure activity with lower glycosuria
by: Yixiang Xu, et al.
Published: (2023)

The Importance of SGLT-2 Inhibitors as Both the Prevention and the Treatment of Diabetic Cardiomyopathy
by: Klaudia Kowalska, et al.
Published: (2022)

Mechanistic evaluation of the inhibitory effect of four SGLT-2 inhibitors on SGLT 1 and SGLT 2 using physiologically based pharmacokinetic (PBPK) modeling approaches
by: Yu Zhang, et al.
Published: (2023)

IMPROVING PRESCRIPTION OF SGLT-2 INHIBITORS IN HEART FAILURE MANAGEMENT AT UT TYLER INTERNAL MEDICINE RESIDENT CLINIC
by: Mariam Qazi, DO, et al.
Published: (2023)

SGLT2 inhibitors for patients with heart failure with preserved ejection fraction in China: a cost-effectiveness study
by: He Lu, et al.
Published: (2023)

Impact of SGLT2 inhibitors treatment on the chronic kidney disease in people with type 2 diabetes
by: Marcin Czarkowski, et al.
Published: (2022)

SGLT2 inhibitors - a breakthrough in treatment of heart failure and their multipotential beneficial role in cardiology, diabetology, nephrology and neurology
by: Marta Bogowska, et al.
Published: (2023)

Cost-Effectiveness of Adding SGLT2 Inhibitors to Standard Treatment for Heart Failure With Reduced Ejection Fraction Patients in China
by: Yaohui Jiang, et al.
Published: (2021)

SGLT-2 inhibitors: Post infarction interventional effects
by: Pugazhenthan Thangaraju, et al.
Published: (2023)

SGLT2 inhibitors and the changing landscape for treatment of diabetes
by: Liu S, et al.
Published: (2019)

SGLT2 inhibitors: control of glycemia and nephroprotection properties
by: A. A. Volodin, et al.
Published: (2018)

SGLT2 inhibitors: suggestions from the amphibian world
by: Stefano Michelassi
Published: (2022)

SGLT2 Inhibitors and Fracture Risk in Elderly Population
by: Vishal R Tandon, et al.
Published: (2023)

Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
by: Kai-Fan Tsai, et al.
Published: (2021)

Reply to SGLT-2 inhibitors: Post-infarction interventional effects
by: Pasquale Paolisso, et al.
Published: (2023)

SGLT2-inhibitors are effective and safe in the elderly: The SOLD study
by: Maria Elena Lunati, et al.
Published: (2022)

Bibliometric and visual analysis of SGLT2 inhibitors in cardiovascular diseases
by: Runfang Pan, et al.
Published: (2024)

Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors Use among Heart Failure Patients and the Role of Pharmacists in Early Initiation of Therapy
by: Mohammed Aldhaeefi, et al.
Published: (2023)

Understanding the Mechanisms and Treatment of Heart Failure: Quantitative Systems Pharmacology Models with a Focus on SGLT2 Inhibitors and Sex-Specific Differences
by: Jean François Ndiaye, et al.
Published: (2023)

The metabolic model of heart failure: the role of sodium glucose co-transporter-2 (SGLT-2) inhibition
by: Muhammad Saad, et al.
Published: (2018)

Pretreatment with KGA-2727, a selective SGLT1 inhibitor, is protective against myocardial infarction-induced ventricular remodeling and heart failure in mice
by: Yohei Sawa, et al.
Published: (2020)